SIGA (SIGA) 10-Q 6 Aug 20 2020 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Jun. 30, 2020	Jul. 30, 2020
Document Information [Line Items]
Entity Central Index Key	0001010086
Entity Registrant Name	Siga Technologies INC
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2020
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2020
Document Transition Report	false
Entity File Number	0-23047
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	13-3864870
Entity Address, Address Line One	31 East 62nd Street
Entity Address, Postal Zip Code	10065
Entity Address, City or Town	New York
Entity Address, State or Province	NY
City Area Code	212
Local Phone Number	672-9100
Title of 12(b) Security	common stock, $.0001 par value
Trading Symbol	SIGA
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		78,120,811

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Current assets
Cash and cash equivalents	$ 53,065,833	$ 65,249,072
Restricted cash and cash equivalents, short-term	0	95,737,862
Accounts receivable	36,611,661	4,167,996
Inventory	14,006,986	9,652,855
Prepaid expenses and other current assets	1,382,499	5,234,000
Total current assets	105,066,979	180,041,785
Property, plant and equipment, net	2,366,135	2,618,303
Deferred tax assets, net	11,183,600	14,151,002
Goodwill	898,334	898,334
Other assets	901,906	856,766
Total assets	120,416,954	198,566,190
Current liabilities
Accounts payable	630,165	3,054,032
Accrued expenses and other current liabilities	14,931,370	8,636,911
Total debt, current	0	80,044,866
Total current liabilities	15,561,535	91,735,809
Warrant liability	7,752,534	6,116,882
Other liabilities	2,969,867	2,929,743
Total liabilities	26,283,936	100,782,434
Commitments and contingencies
Stockholders’ equity
Common stock ($.0001 par value, 600,000,000 shares authorized, 78,618,743 and 81,269,868 issued and outstanding at June 30, 2020, and December 31, 2019, respectively)	7,862	8,127
Additional paid-in capital	221,380,828	220,808,037
Accumulated deficit	(127,255,672)	(123,032,408)
Total stockholders’ equity	94,133,018	97,783,756
Total liabilities and stockholders’ equity	$ 120,416,954	$ 198,566,190

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Jun. 30, 2020	Dec. 31, 2019
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	600,000,000	600,000,000
Common stock, shares issued (in shares)	78,618,743	81,269,868
Common stock, shares outstanding (in shares)	78,618,743	81,269,868

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Revenues
Total revenues	$ 40,348,777	$ 3,907,611	$ 42,968,542	$ 14,366,695
Operating expenses
Cost of sales and supportive services	4,796,768	0	4,905,863	915,367
Selling, general and administrative	3,870,927	3,392,228	7,046,952	6,558,794
Research and development	2,709,743	2,038,323	5,859,847	6,035,604
Patent expenses	174,203	182,310	356,800	370,226
Total operating expenses	11,551,641	5,612,861	18,169,462	13,879,991
Operating income (loss)	28,797,136	(1,705,250)	24,799,080	486,704
(Loss) gain from change in fair value of warrant liability	(1,619,587)	656,523	(1,635,652)	3,792,788
Loss on extinguishment of Term Loan	0	0	(4,981,461)	0
Interest expense	0	(3,971,031)	(3,016,817)	(7,899,449)
Other income, net	31,931	737,577	444,295	1,473,706
Income (loss) before income taxes	27,209,480	(4,282,181)	15,609,445	(2,146,251)
(Provision) benefit for income taxes	(6,319,322)	1,119,689	(3,616,816)	613,536
Net and comprehensive income (loss)	$ 20,890,158	$ (3,162,492)	$ 11,992,629	$ (1,532,715)
Basic income (loss) per share (in dollars per share)	$ 0.26	$ (0.04)	$ 0.15	$ (0.02)
Diluted income (loss) per share (in dollars per share)	$ 0.26	$ (0.05)	$ 0.15	$ (0.06)
Weighted average shares outstanding: basic (in shares)	80,340,695	80,986,524	80,790,400	80,950,124
Weighted average shares outstanding: diluted (in shares)	80,516,863	82,114,661	80,959,812	82,129,601
Product Sales and Supportive Services [Member]
Revenues
Total revenues	$ 38,624,450	$ 0	$ 38,737,459	$ 7,142,400
Research and Development [Member]
Revenues
Total revenues	$ 1,724,327	$ 3,907,611	$ 4,231,083	$ 7,224,295

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Cash flows from operating activities:
Net income/(loss)	$ 11,992,629	$ (1,532,715)
Adjustments to reconcile net income/(loss) to net cash used in operating activities:
Depreciation and other amortization	267,669	265,289
Loss/(gain) on change in fair value of warrant liability	1,635,652	(3,792,788)
Stock-based compensation	582,549	956,284
Deferred income taxes, net	2,967,402	(655,139)
Loss on extinguishment of Term Loan	4,981,461	0
Non-cash interest expense	887,132	2,230,153
Changes in assets and liabilities:
Accounts receivable	(32,443,665)	(2,169,083)
Inventory	(1,751,459)	517,724
Prepaid expenses and other assets	1,203,690	942,599
Accounts payable, accrued expenses and other liabilities	(4,421,690)	(2,304,892)
Deferred revenue	8,332,405	1,204,135
Net cash used in operating activities	(5,766,225)	(4,338,433)
Cash flows from investing activities:
Capital expenditures	(15,501)	(8,948)
Net cash used in investing activities	(15,501)	(8,948)
Cash flows from financing activities:
Payment of employee tax obligations for common stock tendered	(9,746)	(56,590)
Repurchase of common stock	(16,216,170)	0
Repayment of Term Loan	(85,913,459)	0
Net cash used in financing activities	(102,139,375)	(56,590)
Net decrease in cash, cash equivalents and restricted cash	(107,921,101)	(4,403,971)
Cash, cash equivalents and restricted cash at the beginning of period	160,986,934	180,396,910
Cash, cash equivalents and restricted cash at end of period	53,065,833	175,992,939
Supplemental disclosure of non-cash activities:
Conversion of warrants to common stock	0	1,172,801
Issuance of common stock upon cashless exercise	$ 0	$ 118,500

Note 1 - Condensed Consolidated

Note 1 - Condensed Consolidated Financial Statements	6 Months Ended
	Jun. 30, 2020
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	1. Condensed Consolidated Financial Statements The financial statements are presented in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and the rules and regulations of the Securities and Exchange Commission (the “SEC”) for quarterly reports on Form 10 December 31, 2019 2019 10 not 2019 10 March 5, 2020. 2019 not three six June 30, 2020 not

Note 2 - Summary of Significant

Note 2 - Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2020
Notes to Financial Statements
Significant Accounting Policies [Text Block]	2. Revenue Recognition All of the Company’s revenue is derived from long-term contracts that span multiple years. The Company accounts for revenue in accordance with ASC Topic 606, Revenue from Contracts with Customers 606” June 30, 2020 Note 3 six two one June 30, 2020 not Performance Obligations A performance obligation is a promise in a contract to transfer a distinct good or service to the customer, and is the unit of account in ASC 606. Contract modifications may not The Company’s performance obligations are satisfied over time as work progresses or at a point in time. All of the Company’s revenue related to current research and development performance obligations is recognized over time, because the customer simultaneously receives and consumes the benefits provided by the services as the Company performs these services. The Company recognizes revenue related to these services based on the progress toward complete satisfaction of the performance obligation and measures this progress under an input method, which is based on the Company’s cost incurred relative to total estimated costs. Under this method, progress is measured based on the cost of resources consumed (i.e., cost of third third Contract Balances The timing of revenue recognition, billings and cash collections may June 30, 2020 six June 30, 2020 ue of million t Restricted Cash and Cash Equivalents On March 13, 2020, October 31, 2018 t (as required under the Loan Agreement related to the Term Loan). Cash Note 8 second 2019, second 2019. The following tables reconcile cash, cash equivalents and restricted cash per the condensed consolidated statements of cash flows to the condensed consolidated balance sheet for each respective period: As of June 30, 2020 December 31, 2019 Cash and cash equivalents $ 53,065,833 $ 65,249,072 Restricted cash-short term — 95,737,862 Cash, cash equivalents and restricted cash $ 53,065,833 $ 160,986,934 June 30, 2019 December 31, 2018 Cash and cash equivalents $ 100,263,915 $ 100,652,809 Restricted cash-short term 11,248,400 11,452,078 Restricted cash-long term 64,480,624 68,292,023 Cash, cash equivalents and restricted cash $ 175,992,939 $ 180,396,910 Repurchase of shares When shares recognized as equity are repurchased, the amount of the consideration paid, which includes directly attributable costs, is recognized as a deduction from equity. The excess of the purchase price above par value of repurchased shares that are retired is presented as an increase to accumulated deficit (or a reduction of retained earnings, if any).

Note 3 - Procurement Contracts

Note 3 - Procurement Contracts and Research Agreements	6 Months Ended
	Jun. 30, 2020
Notes to Financial Statements
Procurement Contract and Research Agreements [Text Block]	3. 19C On September 10, 2018, June 30, 2020 "19C five may ten 19C May 20, 2019, four four 363,070 three April 29, 2020. four May 2019 363,070 not 19C The base period of performance specifies potential payments of approximately $51.7 million for the following activities: payments of approximately $11.1 million for the delivery of approximately 35,700 courses of oral TPOXX® to the Strategic Stockpile; payments of $8.0 million for the manufacture of 20,000 courses of final drug product of IV TPOXX® ("IV FDP"), of which $3.2 million of payments are related to the manufacture of bulk drug substance ("IV BDS") to be used in the manufacture of IV FDP; payments of approximately $32.0 million to fund advanced development of IV TPOXX®; and payments of approximately $0.6 million for supportive procurement activities. As of June 30, 2020 June 30, 2020 December 31, 2019 The options that have been exercised to date provide for payments up to approximately $127.1 million. There are exercised options for the following activities: payments up to $11.2 million for the procurement of raw materials to be used in the manufacture of at least 363,070 June 30, June July, June 117,000 second 2020, Unexercised options specify potential payments up to approximately $423.7 million in total (if all such options are exercised). There are options for the following activities: payments of up to $337.7 million for the delivery of up to approximately 1,089,000 courses of oral TPOXX® to the Strategic Stockpile; payments of up to $76.8 million for the manufacture of up to 192,000 courses of IV FDP, of which up to $ million of payments would be paid upon the manufacture of IV BDS to be used in the manufacture of IV FDP; payments of up to approximately $3.6 mill The options related to IV TPOXX® are divided into two may none 19C three three 64,000 Revenues in connection with the 19C 19C three June 30, 2020 2019 six June 30, 2020 2019 three six June 30, 2020 six June 30, 2019 2011 On May 13, 2011, no The contract with BARDA (as amended, modified, or supplemented from time to time the "2011 "2011 2011 June 30, 2020 For courses of oral TPOXX® that have been physically delivered to the Strategic Stockpile under the 2011 no not July 13, 2018, no The 2011 July 30, 2018, 2011 84 August 2018. 2011 2011 may not 2015, two The 2011 September 2020. Revenues in connection with the 2011 2011 three June 30, 2020 2019 six June 30, 2020 2019 three six June 30, 2020 2019 International Procurement Contracts On April 3, 2020, four second 2020, June 3, 2019. Under the terms of the International Promotion Agreement, Meridian was granted exclusive rights to market, advertise, promote, offer for sale, or sell oral TPOXX® in a field of use specified in the International Promotion Agreement in all geographic regions except for the United States and South Korea (the “Territory”), and Meridian has agreed not The fee Meridian retains pursuant to the International Promotion Agreement will be a specified percentage of the collected proceeds of sales of oral TPOXX® net of certain expenses, for years in which customer invoiced amounts net of such expenses are less than or equal to a specified threshold, and a higher specified percentage of such collected net proceeds for years in which such net invoiced amounts exceed the specified threshold. Revenue in connection with international procurement contracts for the delivery of product are recognized at a point in time. During the three six June 30, 2020 2.3 Research Agreements and Grants The Company has an R&D program for IV TPOXX®. This program is funded by the 19C February 2024. June 30, 2020 Revenues in connection with the IV Formulation R&D Contract are recognized over time, under an input method using costs incurred to date relative to the total estimated costs of completion. For the three June 30, 2020 2019 six June 30, 2020 2019 three June 30, 2019 not January 2016 March 2019. In July 2019, May 2020, As of June 30, 2020 , the PEP Label Expansion R&D Contract provides for future aggregate research and development funding under the initial award of up to approximately $22.6 million. The period of performance for this contract, as modified, terminates on July 31, 2025. three six June 30, 2020 Contracts and grants include, among other things, options that may may not may not

Note 4 - Inventory

Note 4 - Inventory	6 Months Ended
	Jun. 30, 2020
Notes to Financial Statements
Inventory Disclosure [Text Block]	4. Inventory Inventory includes costs related to the manufacture of TPOXX®. Inventory consisted of the following: As of June 30, 2020 December 31, 2019 Raw materials $ 2,602,672 $ - Work in-process 11,315,916 8,693,457 Finished goods 88,398 959,398 Inventory $ 14,006,986 $ 9,652,855

Note 5 - Property, Plant and Eq

Note 5 - Property, Plant and Equipment	6 Months Ended
	Jun. 30, 2020
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	5. Property, Plant and Equipment Property, plant and equipment consisted of the following: As of June 30, 2020 December 31, 2019 Leasehold improvements $ 2,420,028 $ 2,420,028 Computer equipment 617,298 601,797 Furniture and fixtures 377,859 377,859 Operating lease right-of-use assets 2,944,932 2,944,932 6,360,117 6,344,616 Less - accumulated depreciation and amortization (3,993,982 ) (3,726,313 ) Property, plant and equipment, net $ 2,366,135 $ 2,618,303 Depreciation and amortization expense on property, plant, and equipment was $267,669 and $265,289 for the six June 30, 2020 2019

Note 6 - Accrued Expenses and O

Note 6 - Accrued Expenses and Other Current Liabilities	6 Months Ended
	Jun. 30, 2020
Notes to Financial Statements
Accrued Expenses and Other Liabilities [Text Block]	6. Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities consisted of the following: As of June 30, 2020 December 31, 2019 Compensation $ 1,747,880 $ 2,966,139 Deferred revenue 10,630,746 2,298,341 Interest payable — 977,724 Lease liability, current portion 434,132 419,709 Research and development vendor costs 298,626 707,685 Professional fees 447,451 288,707 Vacation 438,599 256,402 Other 933,936 722,204 Accrued expenses and other current liabilities $ 14,931,370 $ 8,636,911

Note 7 - Financial Instruments

Note 7 - Financial Instruments	6 Months Ended
	Jun. 30, 2020
Notes to Financial Statements
Financial Instruments Disclosure [Text Block]	7. Financial Instruments 2016 On September 2, 2016, Note 8 ten 10 June 30, 2020 The Company accounts for the Warrant in accordance with the authoritative guidance, which requires that free-standing derivative financial instruments with certain anti-dilution and cash settlement features be classified as assets or liabilities at the time of the transaction, and recorded at their fair value. Any changes in the fair value of the derivative instruments are reported in earnings or loss as long as the derivative contracts are classified as assets or liabilities. The Company classified the Warrant as a liability and reports the change in fair value in the statement of operations. As of June 30, 2020 no

Note 8 - Debt

Note 8 - Debt	6 Months Ended
	Jun. 30, 2020
Notes to Financial Statements
Debt Disclosure [Text Block]	8. On March 13, 2020, six June 30, 2020 On September 2, 2016, November 16, 2016 September 30, 2016 ( November 16, 2016), not not no no November 16, 2016. The Term Loan had a maturity date on the earliest to occur of (i) the four Through the three one May 17, 2020) In connection with the issuance of the Loan Agreement, the Company incurred $8.2 million of costs (including interest on amounts held in the escrow account between September 30, 2016 November 15, 2016). $4.0 7 not

Note 9 - Fair Value of Financia

Note 9 - Fair Value of Financial Instruments	6 Months Ended
	Jun. 30, 2020
Notes to Financial Statements
Fair Value Disclosures [Text Block]	9. Fair Value of Financial Instruments The carrying value of cash equivalents, restricted cash, accounts receivable, accounts payable and accrued expenses and other current liabilities approximates fair value due to the relatively short maturity of these instruments. Common stock warrants, which are classified as a liability, are recorded at their fair market value as of each reporting period. The measurement of fair value requires the use of techniques based on observable and unobservable inputs. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect our market assumptions. The inputs create the following fair value hierarchy: • Level 1 • Level 2 not • Level 3 third The Company uses model-derived valuations where certain inputs are unobservable to third 3. Note 7 June 30, 2020 There were no six June 30, 2020 June 30, 2020 December 31, 2019, 1 no 2 June 30, 2020 December 31, 2019, 1 2 The following table presents changes in the liability-classified warrant measured at fair value using Level 3 Fair Value Measurements of Level 3 liability-classified warrant Warrant liability at December 31, 2019 $ 6,116,882 Increase in fair value of warrant liability 1,635,652 Exercise of warrants — Warrant liability at June 30, 2020 $ 7,752,534

Note 10 - Per Share Data

Note 10 - Per Share Data	6 Months Ended
	Jun. 30, 2020
Notes to Financial Statements
Earnings Per Share [Text Block]	10. Per Share Data The Company computes, presents and discloses earnings per share in accordance with the authoritative guidance, which specifies the computation, presentation and disclosure requirements for earnings per share of entities with publicly held common stock or potential common stock. The objective of basic EPS is to measure the performance of an entity over the reporting period by dividing income (loss) by the weighted average shares outstanding. The objective of diluted EPS is consistent with that of basic EPS, except that it also gives effect to all potentially dilutive common shares outstanding during the period. The following is a reconciliation of the basic and diluted loss per share computation: Three Months Ended June 30, Six Months Ended June 30, 2020 2019 2020 2019 Net income/(loss) for basic earnings per share $ 20,890,158 $ (3,162,492 ) $ 11,992,629 $ (1,532,715 ) Less: Change in fair value of warrants — 656,523 — 3,792,788 Net income/(loss), adjusted for change in fair value of warrants for diluted earnings per share $ 20,890,158 $ (3,819,015 ) $ 11,992,629 $ (5,325,503 ) Weighted-average shares 80,340,695 80,986,524 80,790,400 80,950,124 Effect of potential common shares 176,168 1,128,137 169,412 1,179,477 Weighted-average shares: diluted 80,516,863 82,114,661 80,959,812 82,129,601 Income/(loss) per share: basic $ 0.26 $ (0.04 ) $ 0.15 $ (0.02 ) Income/(loss) per share: diluted $ 0.26 $ (0.05 ) $ 0.15 $ (0.06 ) For the three six June 30, 2020 not three six June 30, 2020 three six June 30, 2020 For the three six June 30, 2019 Three Months Ended June 30, Six Months Ended June 30, 2019 2019 Stock options 352,015 364,444 Stock-settled stock appreciation rights — 3,359 Restricted stock units 527,082 518,295 The appreciation of each stock-settled stock appreciation right was capped at a determined maximum value. As a result, the weighted average number shown in the table above for stock-settled stock appreciation rights reflected the weighted average maximum number of shares that could be issued.

Note 11 - Commitments and Conti

Note 11 - Commitments and Contingencies	6 Months Ended
	Jun. 30, 2020
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	11. Commitments and Contingencies From time to time, we may not Purchase Commitments In the course of our business, the Company regularly enters into agreements with third not ds. As of June 30, 2020 , the Company had approximatel million of purchase commitments.

Note 12 - Related Party Transac

Note 12 - Related Party Transactions	6 Months Ended
	Jun. 30, 2020
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	12. Related Party Transactions Board of Directors and Outside Counsel A member of the Company’s Board of Directors is a partner at the Company’s outside counsel. During the three June 30, 2020 2019 six June 30, 2020 2019 d $235,000, re June 30, 2020 Board of Directors-Consulting Agreement On October 13, 2018, two three June 30, 2020 six June 30, 2020 June 30, 2020 Real Estate Leases On May 26, 2017, ten 31 62 nd first sixty-three first six first sixty-fourth first second five On July 31, 2017, January 9, 2013 660 1700, Effectiveness of the Old HQ Sublease Termination Agreement was conditioned upon the commencement of a sublease for the Old HQ between M&F and a new subtenant (the “Replacement M&F Sublease”), which occurred on August 2, 2017. 660 Under the Old HQ Sublease, the Company was obligated to pay fixed rent of approximately $60,000 per month until August 2018 August 31, 2020. 660 Under the Replacement M&F Sublease, the subtenant’s rental obligations were excused for the first two 2 first twelve 12 12 August 24, 2020. For the time period between August 2, 2017 August 31, 2020 ( not may As a result of the above-mentioned transactions, the Company discontinued usage of Old HQ in the third 2017. December 31, 2017 420, Exit or Disposal Obligations

Note 13 - Income Taxes

Note 13 - Income Taxes	6 Months Ended
	Jun. 30, 2020
Notes to Financial Statements
Income Tax Disclosure [Text Block]	13. Income Taxes The Company’s provision for income taxes consists of federal and state taxes, as applicable, in amounts necessary to align the Company’s year-to-date tax provision with the effective rate that it expects to achieve for the full year. Each quarter the Company updates its estimate of the annual effective tax rate and records cumulative adjustments as necessary. On March 27, 2020, 19 740, 163 2019 2020 168 2018, 2019, 2020 five 2019 For the three June 30, 2020 2019 For the six June 30, 2020 2019 The effective tax rate for the three June 30, 2020 three June 30, 2019 three June 30, 2020 2019 162 The effective tax rate for the six June 30, 2020 six June 30, 2020 2019 162

Note 14 - Equity

Note 14 - Equity	6 Months Ended
	Jun. 30, 2020
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	14. The tables below present changes in stockholders' equity for the three six June 30, 2020 2019 Common Stock Additional Paid-in Accumulated Other Comprehensive Total Stockholders' Shares Amount Capital Deficit Income Equity Balances at March 31, 2020 81,047,424 $ 8,105 $ 221,057,307 $ (132,923,290 ) $ — $ 88,142,122 Net income — — 20,890,158 — 20,890,158 Repurchase of common stock (2,548,681 ) (255 ) — (15,222,540 ) — (15,222,795 ) Payment of common stock tendered for employee stock-based compensation tax obligations — — — — — — Issuance of common stock upon vesting of RSUs 120,000 12 (12 ) — — — Stock-based compensation — — 323,533 — — 323,533 Balances at June 30, 2020 78,618,743 $ 7,862 $ 221,380,828 $ (127,255,672 ) $ — $ 94,133,018 Common Stock Additional Paid-in Accumulated Other Comprehensive Total Stockholders' Shares Amount Capital Deficit Income Equity Balances at December 31, 2019 81,269,868 $ 8,127 $ 220,808,037 $ (123,032,408 ) $ — $ 97,783,756 Net income — — — 11,992,629 — 11,992,629 Repurchase of common stock (2,773,775 ) (277 ) — (16,215,893 ) — (16,216,170 ) Payment of common stock tendered for employee stock-based compensation tax obligations (1,892 ) — (9,746 ) — — (9,746 ) Issuance of common stock upon vesting of RSUs 124,542 12 (12 ) — — - Stock-based compensation — — 582,549 — — 582,549 Balances at June 30, 2020 78,618,743 $ 7,862 $ 221,380,828 $ (127,255,672 ) $ — $ 94,133,018 Common Stock Additional Paid-in Accumulated Other Comprehensive Total Stockholders' Shares Amount Capital Deficit Income Equity Balances at March 31, 2019 80,941,524 $ 8,094 $ 220,222,959 $ (114,161,484 ) $ — $ 106,069,569 Net loss — — — (3,162,492 ) — (3,162,492 ) Issuance of common stock upon vesting of RSUs 105,000 11 (11 ) — — — Stock-based compensation — — 547,390 — — 547,390 Balances at June 30, 2019 $ 81,046,524 $ 8,105 $ 220,770,338 $ (117,323,976 ) $ — $ 103,454,467 Common Stock Additional Paid-in Accumulated Other Comprehensive Total Stockholders' Shares Amount Capital Deficit Income Deficiency Balances at December 31, 2018 80,763,350 $ 8,076 $ 218,697,872 $ (115,791,261 ) $ — $ 102,914,687 Net loss — — — (1,532,715 ) — (1,532,715 ) Issuance of common stock upon exercise of stock options 9,769 1 (1 ) — — — Issuance of common stock upon vesting of RSUs and exercise of stock-settled appreciation rights 121,771 13 (13 ) — — — Issuance of common stock upon exercise of warrants 159,782 16 1,172,785 — — 1,172,801 Payment of common stock tendered for employee stock-based compensation tax obligations (8,148 ) (1 ) (56,589 ) — — (56,590 ) Stock-based compensation — — 956,284 — — 956,284 Balances at June 30, 2019 81,046,524 $ 8,105 $ 220,770,338 $ (117,323,976 ) $ — $ 103,454,467 On March 5, 2020, may December 31, 2021. may may 10b5 1 1934, three six June 30, 2020

Note 15 - Leases

Note 15 - Leases	6 Months Ended
	Jun. 30, 2020
Notes to Financial Statements
Lessee, Operating Leases [Text Block]	15. The Company leases its Corvallis, Oregon, facilities and office space under an operating lease, which was signed on November 3, 2017 January 1, 2018. December 31, 2019 two one two three second 2019, first December 31, 2021. On May 26, 2017 ten no Operating lease costs totaled $0.1 million and $0.1 million for the three June 30, 2020 2019 six June 30, 2020 2019 three June 30, 2020 2019 six June 30, 2020 2019 June 30, 2020 Future undiscounted cash flows under operating leases as of June 30, 2020 2020 $ 247,288 2021 600,362 2022 368,467 2023 402,078 2024 404,258 Thereafter 982,880 Total undiscounted cash flows under leases 3,005,333 Less: Imputed interest (418,153 ) Present value of lease liabilities $ 2,587,180 As of June 30, 2020

Significant Accounting Policies

Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2020
Accounting Policies [Abstract]
Revenue from Contract with Customer [Policy Text Block]	Revenue Recognition All of the Company’s revenue is derived from long-term contracts that span multiple years. The Company accounts for revenue in accordance with ASC Topic 606, Revenue from Contracts with Customers 606” June 30, 2020 Note 3 six two one June 30, 2020 not Performance Obligations A performance obligation is a promise in a contract to transfer a distinct good or service to the customer, and is the unit of account in ASC 606. Contract modifications may not The Company’s performance obligations are satisfied over time as work progresses or at a point in time. All of the Company’s revenue related to current research and development performance obligations is recognized over time, because the customer simultaneously receives and consumes the benefits provided by the services as the Company performs these services. The Company recognizes revenue related to these services based on the progress toward complete satisfaction of the performance obligation and measures this progress under an input method, which is based on the Company’s cost incurred relative to total estimated costs. Under this method, progress is measured based on the cost of resources consumed (i.e., cost of third third Contract Balances The timing of revenue recognition, billings and cash collections may June 30, 2020 six June 30, 2020 ue of million t
Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]	Restricted Cash and Cash Equivalents On March 13, 2020, October 31, 2018 t (as required under the Loan Agreement related to the Term Loan). Cash Note 8 second 2019, second 2019. The following tables reconcile cash, cash equivalents and restricted cash per the condensed consolidated statements of cash flows to the condensed consolidated balance sheet for each respective period: As of June 30, 2020 December 31, 2019 Cash and cash equivalents $ 53,065,833 $ 65,249,072 Restricted cash-short term — 95,737,862 Cash, cash equivalents and restricted cash $ 53,065,833 $ 160,986,934 June 30, 2019 December 31, 2018 Cash and cash equivalents $ 100,263,915 $ 100,652,809 Restricted cash-short term 11,248,400 11,452,078 Restricted cash-long term 64,480,624 68,292,023 Cash, cash equivalents and restricted cash $ 175,992,939 $ 180,396,910
Stockholders' Equity, Policy [Policy Text Block]	Repurchase of shares When shares recognized as equity are repurchased, the amount of the consideration paid, which includes directly attributable costs, is recognized as a deduction from equity. The excess of the purchase price above par value of repurchased shares that are retired is presented as an increase to accumulated deficit (or a reduction of retained earnings, if any).

Note 2 - Summary of Significa_2

Note 2 - Summary of Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2020
Notes Tables
Cash, Cash Equivalents and Investments [Table Text Block]	As of June 30, 2020 December 31, 2019 Cash and cash equivalents $ 53,065,833 $ 65,249,072 Restricted cash-short term — 95,737,862 Cash, cash equivalents and restricted cash $ 53,065,833 $ 160,986,934 June 30, 2019 December 31, 2018 Cash and cash equivalents $ 100,263,915 $ 100,652,809 Restricted cash-short term 11,248,400 11,452,078 Restricted cash-long term 64,480,624 68,292,023 Cash, cash equivalents and restricted cash $ 175,992,939 $ 180,396,910

Note 4 - Inventory (Tables)

Note 4 - Inventory (Tables)	6 Months Ended
	Jun. 30, 2020
Notes Tables
Schedule of Inventory, Current [Table Text Block]	As of June 30, 2020 December 31, 2019 Raw materials $ 2,602,672 $ - Work in-process 11,315,916 8,693,457 Finished goods 88,398 959,398 Inventory $ 14,006,986 $ 9,652,855

Note 5 - Property, Plant and _2

Note 5 - Property, Plant and Equipment (Tables)	6 Months Ended
	Jun. 30, 2020
Notes Tables
Property, Plant and Equipment [Table Text Block]	As of June 30, 2020 December 31, 2019 Leasehold improvements $ 2,420,028 $ 2,420,028 Computer equipment 617,298 601,797 Furniture and fixtures 377,859 377,859 Operating lease right-of-use assets 2,944,932 2,944,932 6,360,117 6,344,616 Less - accumulated depreciation and amortization (3,993,982 ) (3,726,313 ) Property, plant and equipment, net $ 2,366,135 $ 2,618,303

Note 6 - Accrued Expenses and_2

Note 6 - Accrued Expenses and Other Current Liabilities (Tables)	6 Months Ended
	Jun. 30, 2020
Notes Tables
Accrued Expenses and Other Current Liabilities [Table Text Block]	As of June 30, 2020 December 31, 2019 Compensation $ 1,747,880 $ 2,966,139 Deferred revenue 10,630,746 2,298,341 Interest payable — 977,724 Lease liability, current portion 434,132 419,709 Research and development vendor costs 298,626 707,685 Professional fees 447,451 288,707 Vacation 438,599 256,402 Other 933,936 722,204 Accrued expenses and other current liabilities $ 14,931,370 $ 8,636,911

Note 9 - Fair Value of Financ_2

Note 9 - Fair Value of Financial Instruments (Tables)	6 Months Ended
	Jun. 30, 2020
Notes Tables
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	Fair Value Measurements of Level 3 liability-classified warrant Warrant liability at December 31, 2019 $ 6,116,882 Increase in fair value of warrant liability 1,635,652 Exercise of warrants — Warrant liability at June 30, 2020 $ 7,752,534

Note 10 - Per Share Data (Table

Note 10 - Per Share Data (Tables)	6 Months Ended
	Jun. 30, 2020
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Three Months Ended June 30, Six Months Ended June 30, 2020 2019 2020 2019 Net income/(loss) for basic earnings per share $ 20,890,158 $ (3,162,492 ) $ 11,992,629 $ (1,532,715 ) Less: Change in fair value of warrants — 656,523 — 3,792,788 Net income/(loss), adjusted for change in fair value of warrants for diluted earnings per share $ 20,890,158 $ (3,819,015 ) $ 11,992,629 $ (5,325,503 ) Weighted-average shares 80,340,695 80,986,524 80,790,400 80,950,124 Effect of potential common shares 176,168 1,128,137 169,412 1,179,477 Weighted-average shares: diluted 80,516,863 82,114,661 80,959,812 82,129,601 Income/(loss) per share: basic $ 0.26 $ (0.04 ) $ 0.15 $ (0.02 ) Income/(loss) per share: diluted $ 0.26 $ (0.05 ) $ 0.15 $ (0.06 )
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Three Months Ended June 30, Six Months Ended June 30, 2019 2019 Stock options 352,015 364,444 Stock-settled stock appreciation rights — 3,359 Restricted stock units 527,082 518,295

Note 14 - Equity (Tables)

Note 14 - Equity (Tables)	6 Months Ended
	Jun. 30, 2020
Notes Tables
Schedule of Stockholders Equity [Table Text Block]	Common Stock Additional Paid-in Accumulated Other Comprehensive Total Stockholders' Shares Amount Capital Deficit Income Equity Balances at March 31, 2020 81,047,424 $ 8,105 $ 221,057,307 $ (132,923,290 ) $ — $ 88,142,122 Net income — — 20,890,158 — 20,890,158 Repurchase of common stock (2,548,681 ) (255 ) — (15,222,540 ) — (15,222,795 ) Payment of common stock tendered for employee stock-based compensation tax obligations — — — — — — Issuance of common stock upon vesting of RSUs 120,000 12 (12 ) — — — Stock-based compensation — — 323,533 — — 323,533 Balances at June 30, 2020 78,618,743 $ 7,862 $ 221,380,828 $ (127,255,672 ) $ — $ 94,133,018 Common Stock Additional Paid-in Accumulated Other Comprehensive Total Stockholders' Shares Amount Capital Deficit Income Equity Balances at December 31, 2019 81,269,868 $ 8,127 $ 220,808,037 $ (123,032,408 ) $ — $ 97,783,756 Net income — — — 11,992,629 — 11,992,629 Repurchase of common stock (2,773,775 ) (277 ) — (16,215,893 ) — (16,216,170 ) Payment of common stock tendered for employee stock-based compensation tax obligations (1,892 ) — (9,746 ) — — (9,746 ) Issuance of common stock upon vesting of RSUs 124,542 12 (12 ) — — - Stock-based compensation — — 582,549 — — 582,549 Balances at June 30, 2020 78,618,743 $ 7,862 $ 221,380,828 $ (127,255,672 ) $ — $ 94,133,018 Common Stock Additional Paid-in Accumulated Other Comprehensive Total Stockholders' Shares Amount Capital Deficit Income Equity Balances at March 31, 2019 80,941,524 $ 8,094 $ 220,222,959 $ (114,161,484 ) $ — $ 106,069,569 Net loss — — — (3,162,492 ) — (3,162,492 ) Issuance of common stock upon vesting of RSUs 105,000 11 (11 ) — — — Stock-based compensation — — 547,390 — — 547,390 Balances at June 30, 2019 $ 81,046,524 $ 8,105 $ 220,770,338 $ (117,323,976 ) $ — $ 103,454,467 Common Stock Additional Paid-in Accumulated Other Comprehensive Total Stockholders' Shares Amount Capital Deficit Income Deficiency Balances at December 31, 2018 80,763,350 $ 8,076 $ 218,697,872 $ (115,791,261 ) $ — $ 102,914,687 Net loss — — — (1,532,715 ) — (1,532,715 ) Issuance of common stock upon exercise of stock options 9,769 1 (1 ) — — — Issuance of common stock upon vesting of RSUs and exercise of stock-settled appreciation rights 121,771 13 (13 ) — — — Issuance of common stock upon exercise of warrants 159,782 16 1,172,785 — — 1,172,801 Payment of common stock tendered for employee stock-based compensation tax obligations (8,148 ) (1 ) (56,589 ) — — (56,590 ) Stock-based compensation — — 956,284 — — 956,284 Balances at June 30, 2019 81,046,524 $ 8,105 $ 220,770,338 $ (117,323,976 ) $ — $ 103,454,467

Note 15 - Leases (Tables)

Note 15 - Leases (Tables)	6 Months Ended
	Jun. 30, 2020
Notes Tables
Lessee, Operating Lease, Liability, Maturity [Table Text Block]	2020 $ 247,288 2021 600,362 2022 368,467 2023 402,078 2024 404,258 Thereafter 982,880 Total undiscounted cash flows under leases 3,005,333 Less: Imputed interest (418,153 ) Present value of lease liabilities $ 2,587,180

Note 2 - Summary of Significa_3

Note 2 - Summary of Significant Accounting Policies (Details Textual) $ in Millions	6 Months Ended
	Jun. 30, 2020USD ($)
Revenue, Remaining Performance Obligation, Amount	$ 142.8
Contract with Customer, Asset, after Allowance for Credit Loss, Total	2.5
Contract with Customer, Liability, Revenue Recognized	$ 0.1

Note 2 - Summary of Significa_4

Note 2 - Summary of Significant Accounting Policies - Cash, Cash Equivalents, and Restricted Cash (Details) - USD ($)	Jun. 30, 2020	Dec. 31, 2019	Jun. 30, 2019	Dec. 31, 2018
Cash and cash equivalents	$ 53,065,833	$ 65,249,072	$ 100,263,915	$ 100,652,809
Restricted cash-short term	0	95,737,862	11,248,400	11,452,078
Cash, cash equivalents and restricted cash	$ 53,065,833	$ 160,986,934	175,992,939	180,396,910
Restricted cash-long term			$ 64,480,624	$ 68,292,023

Note 3 - Procurement Contract_2

Note 3 - Procurement Contracts and Research Agreements (Details Textual) $ in Thousands	Apr. 29, 2020USD ($)	Apr. 03, 2020USD ($)	May 20, 2019USD ($)shares	Jul. 31, 2020USD ($)	Jun. 30, 2020USD ($)	Aug. 31, 2018USD ($)	Jun. 30, 2020USD ($)	Jun. 30, 2019USD ($)	Mar. 31, 2019USD ($)	Jun. 30, 2020USD ($)	Jun. 30, 2019USD ($)	May 31, 2020USD ($)	Mar. 31, 2020USD ($)	Jul. 31, 2019USD ($)	Sep. 10, 2018	May 13, 2011
Contract with Customer, Liability, Revenue Recognized										$ 100
The 19C BARDA Contract [Member]
Number of Courses to Be Delivered															1,488,000
Number of Courses Stored As Vendor Managed Inventory															212,000
Government Contract, Value of Award	$ 602,500
Government Contract, Base Period, Value of Award for Delivery and Support Activities	$ 51,700				$ 51,700		$ 51,700			51,700
Base Period of Performance (Year)	5 years
Government Contract, Value, Payments Remaining Related to Exercised Options	$ 127,100				127,100		127,100			127,100
Government Contract, Value, Payments Currently Specified as Unexercised Options	$ 423,700				423,700		423,700			$ 423,700
Base Period of Performance, Exercise of Options, Term (Year)										10 years
Number of Courses Divided into Procurement-Related Options			363,070
Number of Procurement-related Options, Conversion of Option, Manufacture and Delivery of Courses (in shares) | shares			4
Payments to be Received, Procurement-related Options Providing for Payment for Procurement of Raw Materials			$ 11,200
Number of Procurement-related Options Specifying Delivery of Courses for Consideration (in shares) | shares			3
Courses to be Delivered, Procurement-related Options Specifying Delivery of Courses for Consideration			121,000
Payments to be Received, Procurement-related Options Specifying Delivery of Courses for Consideration			$ 33,800
Payments to be Received, Procurement-related Options			$ 112,500
Government Contract, Base Period, Value of Award for Delivery and Support Activities, Delivery of Courses					$ 11,100		$ 11,100			$ 11,100
Government Contract, Base Period, Number of Deliveries					35,700		35,700			35,700
Government Contract, Base Period, Value of Award for Delivery and Support Activities, Manufacture of Courses					$ 8,000		$ 8,000			$ 8,000
Government Contract, Base Period, Value of Award for Delivery and Support Activities, Advanced Development					32,000		32,000			32,000
Government Contract, Base Period, Value of Award for Delivery and Support Activities, Supportive Procurement Activities					$ 600		600			600
Proceeds from Delivery of Courses										$ 11,100
Number of Courses Delivered					117,000					35,700
Proceeds from Other Base Period Activities										$ 4,700
Contract with Customer, Liability, Total					$ 7,600		7,600			7,600
Government Contract, Value, Payments Related to Exercised Options, Procurement of Raw Materials										11,200
Government Contract, Value, Payments Related to Exercised Options, Funding of Post-Marketing Activities					14,600		14,600			14,600
Contract with Customer, Liability, Revenue Recognized										3,600
Proceeds for the Funding of Post-marketing Activities										2,300
Government Contract, Value, Payments Related to Unexercised Options, Funding of Post-Marketing Activities					3,600		3,600			3,600
Government Contract, Value of Unexercised Options, Supportive Procurement Activities					$ 5,600		5,600			5,600
The 19C BARDA Contract [Member] | Transferred over Time [Member]
Contract with Customer, Liability, Revenue Recognized							1,400	$ 400		3,500	$ 1,700
The 19C BARDA Contract [Member] | Transferred at Point in Time [Member]
Contract with Customer, Liability, Revenue Recognized							$ 36,200			$ 36,200	7,100
The 19C BARDA Contract [Member] | Subsequent Event [Member]
Contract with Customer, Liability, Revenue Recognized				$ 36,200
Proceeds from Customers				32,600
The 19C BARDA Contract [Member] | IV TPOXX [Member]
Government Contract, Base Period, Number of Courses Manufactured					20,000		20,000			20,000
Government Contract, Value, Payments Currently Specified as Unexercised Options, Delivery of Courses					$ 337,700		$ 337,700			$ 337,700
Government Contract, Unexercised Options, Number of Deliveries					1,089,000		1,089,000			1,089,000
Number of Manufacturing Steps					2		2			2
The 19C BARDA Contract [Member] | IV BDS [Member]
Government Contract, Base Period, Value of Award for Delivery and Support Activities, Manufacture of Courses					$ 3,200		$ 3,200			$ 3,200
Proceeds from the Manufacture of Courses										3,200
Contract with Customer, Liability, Total					3,200		3,200			3,200
Government Contract, Value, Payments Currently Specified as Unexercised Options, Manufacture of Courses					$ 30,700		$ 30,700			$ 30,700
Government Contract, Number of Options for Manufacture of Product					3		3			3
Government Contract, Courses Manufactured Upon Exercise of Options					64,000		64,000			64,000
The 19C BARDA Contract [Member] | Oral TPOXX [Member]
Proceeds from Delivery of Courses										$ 101,300
Number of Courses Delivered										363,070
The 19C BARDA Contract [Member] | Product Delivery and Acceptance [Member] | Subsequent Event [Member]
Contract with Customer, Liability, Revenue Recognized				32,600
The 19C BARDA Contract [Member] | Previously Received [Member] | Subsequent Event [Member]
Contract with Customer, Liability, Revenue Recognized				$ 3,600
The 19C BARDA Contract [Member] | IV FDP [Member]
Government Contract, Value, Payments Currently Specified as Unexercised Options, Manufacture of Courses					$ 76,800		$ 76,800			$ 76,800
Government Contract, Value, Unexercised Options, Manufacture of Courses					192,000		192,000			192,000
Government Contract, Number of Options for Manufacture of Product					3		3			3
Government Contract, Courses Manufactured Upon Exercise of Options					64,000		64,000			64,000
The 2011 BARDA Contract [Member]
Number of Courses to Be Delivered																1,700,000
Government Contract, Value of Award					$ 508,400		$ 508,400			$ 508,400
Government Contract, Value, Payments Remaining Related to Exercised Options													$ 72,700
Number of Additional Courses to be Delivered at No Additional Cost																300,000
Proceeds from the Manufacture and Delivery of Courses										$ 459,800
Number of Courses to be Manufactured					1,700,000		1,700,000			1,700,000
Proceeds from Reimbursements in Connection with Development and Supportive Activities										$ 45,400
Amount Eligible to be Received for Reimbursements of Development and Supportive Activities					$ 3,200		$ 3,200			3,200
Proceeds from Government Contract Options, Exercised						$ 50,000
Government Contract, Increase (Decrease) in Value of Award, FDA Approval						$ 50,000
Government Contract, Value, Payments Related to Exercised Options, Development and Supportive Activities													58,300
Government Contract, Value, Payments Related to Exercised Options, Production-related Activities													$ 14,400
The 2011 BARDA Contract [Member] | Transferred over Time [Member]
Contract with Customer, Liability, Revenue Recognized							100	100		100	200
The 2011 BARDA Contract [Member] | Transferred at Point in Time [Member]
Contract with Customer, Liability, Revenue Recognized							0	0		0	0
Canadian Contract [Member] | Meridian Medical Technologies [Member]
Government Contract, Term (Year)		4 years
Government Contract Receivable		$ 14,300			$ 2,300		$ 2,300			$ 2,300
Government Contract, Number of Courses Purchased					2,500		2,500			2,500
Canadian Contract [Member] | Meridian Medical Technologies [Member] | Maximum [Member]
Government Contract, Number of Courses to Be Purchased		15,325
International Procurement Contracts [Member] | Transferred at Point in Time [Member]
Contract with Customer, Liability, Revenue Recognized							$ 2,300			$ 2,300
The IV Formulation R & D Contract with BARDA [Member]
Government Contract, Future Aggregate Research and Development Funding					$ 2,200		2,200			2,200
The IV Formulation R & D Contract with BARDA [Member] | Transferred over Time [Member]
Contract with Customer, Liability, Revenue Recognized							300	$ 3,400		700	$ 5,300
Contract with Customer, Asset, Cumulative Catch-up Adjustment to Revenue, Change in Estimate of Transaction Price									$ 3,300
The PEP Label Expansion R & D Contract with the Department of Defense [Member]
Grants Receivable												$ 26,000		$ 19,500
Government Contract, Initial Award					$ 22,600		22,600			22,600		$ 23,000		$ 12,400
The PEP Label Expansion R & D Contract with the Department of Defense [Member] | Transferred over Time [Member]
Contract with Customer, Liability, Revenue Recognized							$ 100			$ 100

Note 4 - Inventory - Inventory

Note 4 - Inventory - Inventory (Details) - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Raw materials	$ 2,602,672	$ 0
Work in-process	11,315,916	8,693,457
Finished goods	88,398	959,398
Inventory	$ 14,006,986	$ 9,652,855

Note 5 - Property, Plant and _3

Note 5 - Property, Plant and Equipment (Details Textual) - USD ($)	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Depreciation, Depletion and Amortization, Total	$ 267,669	$ 265,289

Note 5 - Property, Plant and _4

Note 5 - Property, Plant and Equipment - Property, Plant and Equipment (Details) - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Property, plant and equipment, gross	$ 6,360,117	$ 6,344,616
Operating lease right-of-use assets	2,944,932	2,944,932
Less - accumulated depreciation and amortization	(3,993,982)	(3,726,313)
Property, plant and equipment, net	2,366,135	2,618,303
Leasehold Improvements [Member]
Property, plant and equipment, gross	2,420,028	2,420,028
Computer Equipment [Member]
Property, plant and equipment, gross	617,298	601,797
Furniture and Fixtures [Member]
Property, plant and equipment, gross	$ 377,859	$ 377,859

Note 6 - Accrued Expenses and_3

Note 6 - Accrued Expenses and Other Current Liabilities - Accrued Expenses and Other Current Liabilities (Details) - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Compensation	$ 1,747,880	$ 2,966,139
Deferred revenue	10,630,746	2,298,341
Interest payable	0	977,724
Lease liability, current portion	434,132	419,709
Research and development vendor costs	298,626	707,685
Professional fees	447,451	288,707
Vacation	438,599	256,402
Other	933,936	722,204
Accrued expenses and other current liabilities	$ 14,931,370	$ 8,636,911

Note 7 - Financial Instruments

Note 7 - Financial Instruments (Details Textual) $ / shares in Units, shares in Millions	Jun. 30, 2020USD ($)yrshares	Dec. 31, 2019USD ($)	Sep. 02, 2016USD ($)$ / sharesshares
Warrants and Rights Outstanding | $	$ 7,752,534	$ 6,116,882
The 2016 Warrant [Member]
Class of Warrant or Right Outstanding, Common Stock Value Used to Determine Number of Shares Called | $			$ 4,000,000
Class of Warrant or Right Outstanding, Common Stock Price Per Share Used to Determine Number of Shares Called (in dollars per share) | $ / shares			$ 2.29
Warrants and Rights Outstanding, Term (Year)			10 years
Class of Warrant or Right, Subscription Price of Warrants or Rights (in dollars per share) | $ / shares			$ 1.50
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares			$ 1.50
Class of Warrant or Right, Outstanding (in shares) | shares	1.5		2.7
Warrants and Rights Outstanding | $	$ 7,800,000
The 2016 Warrant [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrants and Rights Outstanding, Measurement Input	0.41
The 2016 Warrant [Member] | Measurement Input, Expected Dividend Rate [Member]
Warrants and Rights Outstanding, Measurement Input	0
The 2016 Warrant [Member] | Measurement Input, Expected Term [Member]
Warrants and Rights Outstanding, Measurement Input | yr	6.17
The 2016 Warrant [Member] | Measurement Input, Price Volatility [Member]
Warrants and Rights Outstanding, Measurement Input	75

Note 8 - Debt (Details Textual)

Note 8 - Debt (Details Textual) - USD ($)	Mar. 13, 2020	Nov. 16, 2016	Sep. 30, 2016	Sep. 02, 2016	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Repayments of Long-term Debt, Principal							$ 85,913,459	$ 0
Gain (Loss) on Extinguishment of Debt, Total					$ 0	$ 0	(4,981,461)	$ 0
Warrants and Rights Outstanding					$ 7,752,534		7,752,534		$ 6,116,882
Warrant Issued Alongside Entry Into the Loan Agreement [Member]
Warrants and Rights Outstanding				$ 5,800,000
Loan Agreement [Member] | Term Loan [Member] | OCM Strategic Credit SIGTEC Holdings, LLC [Member]
Repayments of Long-term Debt Including Interest	$ 87,200,000
Repayments of Long-term Debt, Principal	80,000,000
Repayments of Long-term Debt, Repayment Fee	4,000,000
Interest Paid, Including Capitalized Interest, Operating and Investing Activities, Total	1,200,000
Repayments of Long-term Debt, Prepayment Premium	$ 1,900,000
Gain (Loss) on Extinguishment of Debt, Total							$ (5,000,000)
Proceeds from Issuance of Debt		$ 80,000,000
Proceeds from Issuance of Debt, Placed in Escrow			$ 80,000,000
Debt Instrument, Term (Year)				4 years
Debt Instrument, Repayment Fee				$ 4,000,000
Debt Issuance Costs, Gross				$ 8,200,000
Loan Agreement [Member] | Term Loan [Member] | OCM Strategic Credit SIGTEC Holdings, LLC [Member] | London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument, Basis Spread on Variable Rate				11.50%
Loan Agreement [Member] | Term Loan [Member] | OCM Strategic Credit SIGTEC Holdings, LLC [Member] | US Treasury (UST) Interest Rate [Member]
Debt Instrument, Basis Spread on Variable Rate				0.50%

Note 9 - Fair Value of Financ_3

Note 9 - Fair Value of Financial Instruments (Details Textual) - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Warrants and Rights Outstanding	$ 7,752,534	$ 6,116,882
Fair Value, Inputs, Level 1 [Member]
Cash and Cash Equivalents, Fair Value Disclosure	41,900,000	56,700,000
Restricted Cash and Cash Equivalents, Total		5,600,000
Fair Value, Inputs, Level 2 [Member]
Cash and Cash Equivalents, Fair Value Disclosure	0
Restricted Cash and Cash Equivalents, Total		$ 90,000,000
The 2016 Warrant [Member]
Warrants and Rights Outstanding	$ 7,800,000

Note 9 - Fair Value of Financ_4

Note 9 - Fair Value of Financial Instruments - Changes in the Liability-classified Warrant Measured at Fair Value (Details)	6 Months Ended
	Jun. 30, 2020USD ($)
Warrant liability	$ 6,116,882
Increase in fair value of warrant liability	1,635,652
Exercise of warrants	0
Warrant liability	$ 7,752,534

Note 10 - Per Share Data (Detai

Note 10 - Per Share Data (Details Textual) - shares	3 Months Ended	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2020
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)	1,140,713	1,108,753

Note 10 - Per Share Data - Reco

Note 10 - Per Share Data - Reconciliation of the Basic and Diluted Loss Per Share (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Net income/(loss)	$ 20,890,158	$ (3,162,492)	$ 11,992,629	$ (1,532,715)
Less: Change in fair value of warrants	0	656,523	0	3,792,788
Net income/(loss), adjusted for change in fair value of warrants for diluted earnings per share	$ 20,890,158	$ (3,819,015)	$ 11,992,629	$ (5,325,503)
Weighted average shares outstanding: basic (in shares)	80,340,695	80,986,524	80,790,400	80,950,124
Effect of potential common shares (in shares)	176,168	1,128,137	169,412	1,179,477
Weighted average shares outstanding: diluted (in shares)	80,516,863	82,114,661	80,959,812	82,129,601
Basic income (loss) per share (in dollars per share)	$ 0.26	$ (0.04)	$ 0.15	$ (0.02)
Diluted income (loss) per share (in dollars per share)	$ 0.26	$ (0.05)	$ 0.15	$ (0.06)

Note 10 - Per Share Data - Anti

Note 10 - Per Share Data - Antidilutive Securities Excluded from Computation (Details) - shares	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Share-based Payment Arrangement, Option [Member]
Antidilutive securities (in shares)	352,015	364,444
Stock Appreciation Rights (SARs) [Member]
Antidilutive securities (in shares)	0	3,359
Restricted Stock Units (RSUs) [Member]
Antidilutive securities (in shares)	527,082	518,295

Note 11 - Commitments and Con_2

Note 11 - Commitments and Contingencies (Details Textual) $ in Millions	Jun. 30, 2020USD ($)
Purchase Commitment, Remaining Minimum Amount Committed	$ 21.3

Note 12 - Related Party Trans_2

Note 12 - Related Party Transactions (Details Textual)	Oct. 13, 2018USD ($)	Jul. 31, 2017USD ($)	May 26, 2017USD ($)ft²	Jan. 09, 2013USD ($)ft²	Jun. 30, 2020USD ($)	Jun. 30, 2019USD ($)	Jun. 30, 2020USD ($)	Jun. 30, 2019USD ($)	Dec. 31, 2017USD ($)	Mar. 31, 2020USD ($)	Aug. 02, 2017USD ($)
Lessee, Operating Lease, Liability, to be Paid, Total					$ 3,005,333		$ 3,005,333
Leasehold Improvements and Furniture and Fixtures [Member]
Impairment of Long-Lived Assets to be Disposed of									$ 100,000
Outside Counsel [Member]
Legal Fees					184,000	$ 122,000	303,000	$ 235,000
Accounts Payable, Related Parties					106,000		106,000
Dr. Eric A. Rose [Member] | Consulting Agreement [Member]
Accounts Payable, Related Parties					50,000		50,000
Consulting Agreement, Term (Year)	2 years
Related Party Transaction, Annual Amount	$ 200,000
Related Party Transaction, Expenses from Transactions with Related Party					$ 50,000		$ 100,000
MacAndrews and Forbes Incorporated [Member] | The New HQ Lease [Member]
Lessee, Operating Lease, Term of Contract (Year)			10 years
Area of Real Estate Property (Square Foot) | ft²			3,200
Monthly Rent During Initial Period			$ 25,333
Monthly Rent, Initial Period (Month)			63 months
Monthly Rent After Initial Period			$ 29,333
Monthly Facility Fee, Second Year			$ 3,333
Monthly Facility Fee, Yearly Rate Increase After Second Year			5.00%
Monthly Facility Fee, Final Year			$ 4,925
Lessee, Operating Lease, Liability, to be Paid, Total											$ 900,000
MacAndrews and Forbes Incorporated [Member] | The Old HQ Sublease [Member]
Area of Real Estate Property (Square Foot) | ft²				6,676
Monthly Rent During Initial Period				$ 60,000
Monthly Rent After Initial Period				$ 63,400
Lessee, Operating Lease, Liability, Estimate to be Paid Had No Changes Occurred										$ 2,400,000
Business Exit Costs									$ 1,100,000
MacAndrews and Forbes Incorporated [Member] | The Replacement M&F Sublease [Member]
Rent Concession Period (Month)		2 months
Monthly Rent, First Twelve Months		$ 36,996
Monthly Rent, Year Two		37,831
Monthly Rent, Thereafter		$ 38,665
MacAndrews and Forbes Incorporated [Member] | The Old HQ Sublease Termination Agreement [Member]
Lessee, Operating Lease, Liability, to be Paid, Total											1,100,000
MacAndrews and Forbes Incorporated [Member] | The New HQ Lease and Old HQ Sublease Termination Agreements [Member]
Lessee, Operating Lease, Liability, to be Paid, Total											$ 2,000,000

Note 13 - Income Taxes (Details

Note 13 - Income Taxes (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Tax Adjustments, Settlements, and Unusual Provisions			$ 19,000
Income Taxes Receivable	$ 700,000		700,000
Income (Loss) Attributable to Parent, before Tax, Total	27,200,000	$ (4,300,000)	15,600,000	$ (2,100,000)
Income Tax Expense (Benefit), Total	$ 6,319,322	$ (1,119,689)	$ 3,616,816	$ (613,536)
Effective Income Tax Rate Reconciliation, Percent, Total	23.20%	26.20%	23.20%	28.60%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	21.00%	21.00%	21.00%	21.00%
Deferred Tax Assets, Net of Valuation Allowance, Total			$ (700,000)

Note 14 - Equity (Details Textu

Note 14 - Equity (Details Textual) - USD ($) shares in Millions	3 Months Ended	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2020	Mar. 05, 2020
Stock Repurchase Program, Authorized Amount			$ 50,000,000
Stock Repurchased During Period, Shares (in shares)	2.5	2.8
Stock Repurchased During Period, Value	$ 15,222,795	$ 16,216,170

Note 14 - Equity - Changes in S

Note 14 - Equity - Changes in Stockholders' Equity (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Balances	$ 88,142,122	$ 106,069,569	$ 97,783,756	$ 102,914,687
Net income/(loss)	$ 20,890,158	(3,162,492)	$ 11,992,629	(1,532,715)
Repurchase of common stock (in shares)	(2,500,000)		(2,800,000)
Repurchase of common stock	$ (15,222,795)		$ (16,216,170)
Payment of common stock tendered for employee stock-based compensation tax obligations	0		(9,746)	(56,590)
Issuance of common stock upon vesting of RSUs	0	0	0
Stock-based compensation	323,533	547,390	582,549	956,284
Balances	$ 94,133,018	$ 103,454,467	$ 94,133,018	103,454,467
Issuance of common stock upon exercise of stock options				0
Issuance of common stock upon vesting of RSUs and exercise of stock-settled appreciation rights				0
Issuance of common stock upon exercise of warrants				$ 1,172,801
Common Stock [Member]
Balances (in shares)	81,047,424	80,941,524	81,269,868	80,763,350
Balances	$ 8,105	$ 8,094	$ 8,127	$ 8,076
Net income/(loss)	$ 0	$ 0	$ 0	0
Repurchase of common stock (in shares)	(2,548,681)		(2,773,775)
Repurchase of common stock	$ (255)		$ (277)
Payment of common stock tendered for employee stock-based compensation tax obligations	$ 0		$ 0	(1)
Issuance of common stock upon vesting of RSUs (in shares)	120,000	105,000	124,542
Issuance of common stock upon vesting of RSUs	$ 12	$ 11	$ 12
Stock-based compensation	$ 0	$ 0	$ 0	$ 0
Balances (in shares)	78,618,743	81,046,524	78,618,743	81,046,524
Balances	$ 7,862	$ 8,105	$ 7,862	$ 8,105
Payment of common stock tendered for employee stock-based compensation tax obligations (in shares)			(1,892)	(8,148)
Issuance of common stock upon exercise of stock options (in shares)				9,769
Issuance of common stock upon exercise of stock options				$ 1
Issuance of common stock upon vesting of RSUs and exercise of stock-settled appreciation rights (in shares)				121,771
Issuance of common stock upon vesting of RSUs and exercise of stock-settled appreciation rights				$ 13
Issuance of common stock upon exercise of warrants (in shares)				159,782
Issuance of common stock upon exercise of warrants				$ 16
Additional Paid-in Capital [Member]
Balances	221,057,307	220,222,959	$ 220,808,037	218,697,872
Net income/(loss)	0	0	0	0
Repurchase of common stock	0		0
Payment of common stock tendered for employee stock-based compensation tax obligations	0		(9,746)	(56,589)
Issuance of common stock upon vesting of RSUs	(12)	(11)	(12)
Stock-based compensation	323,533	547,390	582,549	956,284
Balances	221,380,828	220,770,338	221,380,828	220,770,338
Issuance of common stock upon exercise of stock options				(1)
Issuance of common stock upon vesting of RSUs and exercise of stock-settled appreciation rights				(13)
Issuance of common stock upon exercise of warrants				1,172,785
Retained Earnings [Member]
Balances	(132,923,290)	(114,161,484)	(123,032,408)	(115,791,261)
Net income/(loss)	20,890,158	(3,162,492)	11,992,629	(1,532,715)
Repurchase of common stock	(15,222,540)		(16,215,893)
Payment of common stock tendered for employee stock-based compensation tax obligations	0		0	0
Issuance of common stock upon vesting of RSUs	0	0	0
Stock-based compensation	0	0	0	0
Balances	(127,255,672)	(117,323,976)	(127,255,672)	(117,323,976)
Issuance of common stock upon exercise of stock options				0
Issuance of common stock upon vesting of RSUs and exercise of stock-settled appreciation rights				0
Issuance of common stock upon exercise of warrants				0
AOCI Attributable to Parent [Member]
Balances	0	0	0	0
Net income/(loss)	0	0	0	0
Repurchase of common stock	0		0
Payment of common stock tendered for employee stock-based compensation tax obligations	0		0	0
Issuance of common stock upon vesting of RSUs	0	0	0
Stock-based compensation	0	0	0	0
Balances	$ 0	$ 0	$ 0	0
Issuance of common stock upon exercise of stock options				0
Issuance of common stock upon vesting of RSUs and exercise of stock-settled appreciation rights				0
Issuance of common stock upon exercise of warrants				$ 0

Note 15 - Leases (Details Textu

Note 15 - Leases (Details Textual)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2020USD ($)	Jun. 30, 2019USD ($)	Jun. 30, 2020USD ($)	Jun. 30, 2019USD ($)	Dec. 31, 2019	May 26, 2017ft²
Lessee, Operating Lease, First Renewal Term (Year)					2 years
Lessee, Operating Lease, Second Renewal Term (Year)					3 years
Operating Lease, Cost	$ 100,000	$ 100,000	$ 300,000	$ 300,000
Operating Lease, Payments	$ 100,000	$ 100,000	$ 300,000	$ 300,000
Operating Lease, Weighted Average Remaining Lease Term (Year)	5 years 11 months 12 days		5 years 11 months 12 days
Operating Lease, Weighted Average Discount Rate, Percent	4.53%		4.53%
Operating Lease, Liability, Total	$ 2,587,180		$ 2,587,180
Other Liabilities [Member]
Operating Lease, Liability, Total	$ 2,200,000		$ 2,200,000
MacAndrews and Forbes Incorporated [Member] | The New HQ Lease [Member]
Lessee, Operating Lease, Term of Contract (Year)						10 years
Area of Real Estate Property (Square Foot) | ft²						3,200

Note 15 - Leases - Future Undis

Note 15 - Leases - Future Undiscounted Cash Flows Under Operating Leases (Details)	Jun. 30, 2020USD ($)
2020	$ 247,288
2021	600,362
2022	368,467
2023	402,078
2024	404,258
Thereafter	982,880
Total undiscounted cash flows under leases	3,005,333
Less: Imputed interest	(418,153)
Present value of lease liabilities	$ 2,587,180